Reuters logo
BRIEF-Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for enhanze technology
September 14, 2017 / 11:09 AM / a month ago

BRIEF-Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for enhanze technology

Sept 14 (Reuters) - Bristol-Myers Squibb Co

* Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for enhanze technology

* Bristol-Myers Squibb Co - ‍Halozyme to receive $105 million upfront payment, plus future milestones and royalties​

* Bristol-Myers Squibb Co - ‍Halozyme to receive $105 million upfront payment, plus future milestones and royalties​

* Bristol-Myers Squibb Co - ‍provides Bristol-Myers Squibb access to enhanze technology for up to 11 targets​

* Bristol-Myers Squibb Co - ‍collaboration may extend to a maximum of 11 targets​

* Bristol-Myers Squibb Co - ‍for Bristol-Myers Squibb, transaction is expected to be dilutive to non-gaap earnings per share in 2017​

* Bristol-Myers - ‍Halozyme has potential to earn milestone payments of upto $160 million for each nominated collaboration targets,additional milestone payments​

* Bristol-Myers Squibb says ‍for co, deal is expected to be dilutive to non-GAAP earnings per share in 2017 and 2018 by approximately $0.01​

* Bristol-Myers Squibb Co - ‍for co, deal is expected to be dilutive to non-GAAP earnings per share by about $0.05 in 2019​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below